Newronika, a pioneering company in the field of deep brain stimulation (DBS), has successfully raised €13.6 million in a Series B funding round. The financing was led by Fondazione ENEA Tech e Biomedical, marking its entry as a new investor, alongside continued support from Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. With this latest investment, Newronika is set to accelerate the clinical validation and commercialization of its adaptive DBS platform, a next-generation neuromodulation technology designed to enhance treatment outcomes for patients with movement disorders such as Parkinson’s disease.

Advancing Adaptive Deep Brain Stimulation

The company’s innovative adaptive DBS system utilizes real-time neural data to optimize therapy, improving symptom relief while minimizing side effects. This approach represents a significant advancement over traditional DBS systems, which operate on fixed stimulation parameters without adapting to patients’ evolving neurological needs. The new funding will also enable Newronika to strengthen its product pipeline, expand its team with top-tier talent, and forge strategic collaborations that further establish its leadership in the intersection of neuroscience and medical device engineering.

Regulatory and Research Milestones

Newronika’s progress has been underscored by recent achievements, including an Investigational Device Exemption (IDE) approval from the FDA and a grant from The Michael J. Fox Foundation. These milestones highlight the company’s role in shaping the future of neuromodulation, reinforcing its commitment to delivering cutting-edge solutions to patients worldwide. With regulatory momentum and strong investor confidence, Newronika is poised to advance its mission of redefining DBS therapy through precision medicine.

Leadership Perspectives

Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika, emphasized the importance of this funding in driving innovation and improving patient care. He expressed gratitude for the trust shown by both new and existing investors, stating that the Series B round validates the company’s vision of integrating real-time neural data and machine learning into DBS systems. According to Rossi, Newronika is committed to delivering personalized therapies that surpass the capabilities of existing devices, ultimately transforming how deep brain stimulation is administered.

Maria Cristina Porta, General Manager of ENEA Tech e Biomedical, highlighted the transformative potential of Newronika’s technology. She noted that the company’s approach to real-time, personalized neuromodulation aligns with ENEA Tech e Biomedical’s goal of supporting disruptive medical innovations. By investing in Newronika, the firm aims to contribute to groundbreaking advancements in movement disorder treatments while fostering growth and innovation within Italy’s healthcare ecosystem.

Investor Confidence and Future Growth

Indaco Venture Partners, a key returning investor, reaffirmed its confidence in Newronika’s vision and technological capabilities. Davide Turcot, CEO of Indaco, stated that the firm is proud to continue its support through the Indaco Venture I - Lombardia Parallel Fund. He emphasized that Newronika’s adaptive DBS system has the potential to significantly enhance the quality of life for Parkinson’s patients by offering more effective and individualized treatment solutions.

Claudio Giuliano, Chairman of Newronika, described the successful Series B financing round as a pivotal moment for the company’s strategic growth. He noted that the funding solidifies Newronika’s commitment to pushing the boundaries of DBS technology, reinforcing its role as a leader in the neuromodulation space. With continued advancements, the company remains dedicated to improving patient outcomes and setting new standards in personalized brain stimulation.

Headquartered in Milan, Newronika has emerged as a global innovator in adaptive DBS, combining expertise in neuroscience, engineering, and artificial intelligence to redefine the field. The company’s technology has already secured a CE Mark and is now advancing towards broader regulatory approvals, paving the way for expanded commercialization. With strong investor backing and a clear vision, Newronika is well-positioned to drive the next wave of innovation in the treatment of neurological disorders.